Study Stopped
Terminated due to insufficient efficacy over placebo in Study ATL1251/038/CL.
Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
A Phase III, Multicenter, Open Label, Extension Study to Evaluate the Long-Term Safety of Renzapride 4 mg Once Daily in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
1 other identifier
interventional
939
1 country
126
Brief Summary
The main purpose of this study is to evaluate the long-term safety and tolerability of renzapride at a dose of 4 mg taken once daily for 12 months in women with constipation-predominant irritable bowel syndrome (IBS-C).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Apr 2006
126 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2006
CompletedFirst Submitted
Initial submission to the registry
January 23, 2008
CompletedFirst Posted
Study publicly available on registry
February 6, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2008
CompletedJuly 8, 2008
July 1, 2008
2.2 years
January 23, 2008
July 4, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Adverse events
One year
Secondary Outcomes (1)
Vital signs, routine clinical laboratory data, 12-lead ECG
One year
Study Arms (1)
1
EXPERIMENTALAll subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
Interventions
All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
Eligibility Criteria
You may qualify if:
- completed 12 weeks treatment in the preceding pivotal study ATL1251/038/CL
You may not qualify if:
- Subjects who are pregnant or breastfeeding
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Alizymelead
Study Sites (126)
Research Site
Huntsville, Alabama, 35801, United States
Research Site
Chandler, Arizona, 85225, United States
Research Site
Phoenix, Arizona, 85014, United States
Research Site
Sierra Vista, Arizona, 85635, United States
Research Site
Little Rock, Arkansas, 72205, United States
Research Site
North Little Rock, Arkansas, 72117, United States
Research Site
Anaheim, California, 92801, United States
Research Site
Beverly Hills, California, 90211, United States
Research Site
Burbank, California, 91505, United States
Research Site
Carmichael, California, 95608, United States
Research Site
Cerritos, California, 90703, United States
Research Site
Chula Vista, California, 91910, United States
Research Site
Cypress, California, 90630, United States
Research Site
Laguna Hills, California, 92653, United States
Research Site
Los Angeles, California, 90045, United States
Research Site
Orange, California, 92868, United States
Research Site
Orange, California, 92869, United States
Research Site
San Carlos, California, 94070, United States
Research Site
San Diego, California, 92123, United States
Research Site
San Diego, California, 92128, United States
Research Site
San Francisco, California, 94115, United States
Research Site
Colorado Springs, Colorado, 80904, United States
Research Site
Lakewood, Colorado, 80215, United States
Research Site
Littleton, Colorado, 80120, United States
Research Site
Bristol, Connecticut, 06010, United States
Research Site
Boynton Beach, Florida, 33426, United States
Research Site
Coral Gables, Florida, 33134, United States
Research Site
Gainesville, Florida, 32607, United States
Research Site
Hialeah, Florida, 33013, United States
Research Site
Inverness, Florida, 34452, United States
Research Site
Jacksonville, Florida, 32207, United States
Research Site
Jacksonville, Florida, 32256, United States
Research Site
Kissimmee, Florida, 34741, United States
Research Site
Miami, Florida, 33173, United States
Research Site
New Port Richey, Florida, 34652, United States
Research Site
Palm Harbor, Florida, 34684, United States
Research Site
Pembrook Pines, Florida, 33024, United States
Research Site
Pensacola, Florida, 32514, United States
Research Site
Plantation, Florida, 33324, United States
Research Site
Port Orange, Florida, 32129, United States
Research Site
Vero Beach, Florida, 32960, United States
Research Site
West Palm Beach, Florida, 33409-3509, United States
Research Site
Marietta, Georgia, 30067, United States
Research Site
Newnan, Georgia, 30263, United States
Research Site
Rockford, Illinois, 61107-5078, United States
Research Site
Indianapolis, Indiana, 46237, United States
Research Site
Des Moines, Iowa, 50321, United States
Research Site
Arkansas City, Kansas, 67005, United States
Research Site
Overland Park, Kansas, 66251, United States
Research Site
Topeka, Kansas, 66606, United States
Research Site
Wichita, Kansas, 67205, United States
Research Site
Wichita, Kansas, 67207, United States
Research Site
Shreveport, Louisiana, 71103, United States
Research Site
Annapolis, Maryland, 21401, United States
Research Site
Hagerstown, Maryland, 21740, United States
Research Site
Laurel, Maryland, 20707, United States
Research Site
Pasadena, Maryland, 21122, United States
Research Site
Severna Park, Maryland, 21146, United States
Research Site
Boston, Massachusetts, 02114, United States
Research Site
Boston, Massachusetts, 02215, United States
Research Site
Chesterfield, Michigan, 48047, United States
Research Site
Kalamazoo, Michigan, 49048, United States
Research Site
Lansing, Michigan, 48910, United States
Research Site
Troy, Michigan, 48098, United States
Research Site
Tupelo, Mississippi, 38802, United States
Research Site
Mexico, Missouri, 65265, United States
Research Site
Springfield, Missouri, 65807, United States
Research Site
Scottsbluff, Nebraska, 69361, United States
Research Site
Cedar Knolls, New Jersey, 07927, United States
Research Site
Passaic, New Jersey, 07055, United States
Research Site
Sicklerville, New Jersey, 08090, United States
Research Site
Great Neck, New York, 11021, United States
Research Site
Great Neck, New York, 11023, United States
Research Site
Johnson City, New York, 13790, United States
Research Site
Kingston, New York, 12401, United States
Research Site
Mineola, New York, 11501, United States
Research Site
New York, New York, 10021, United States
Research Site
Burlington, North Carolina, 27215, United States
Research Site
Charlotte, North Carolina, 28209, United States
Research Site
Elkin, North Carolina, 28621, United States
Research Site
Fayetteville, North Carolina, 28304, United States
Research Site
Greensboro, North Carolina, 27403, United States
Research Site
Greensboro, North Carolina, 27408, United States
Research Site
New Bern, North Carolina, 28562, United States
Research Site
Pinehurst, North Carolina, 28374, United States
Research Site
Raleigh, North Carolina, 27612, United States
Research Site
Wilmington, North Carolina, 28401, United States
Research Site
Wilmington, North Carolina, 28412, United States
Research Site
Winston-Salem, North Carolina, 27103, United States
Research Site
Bismarck, North Dakota, 58501, United States
Research Site
Fargo, North Dakota, 58104, United States
Research Site
Cincinnati, Ohio, 45242, United States
Research Site
Columbus, Ohio, 43215, United States
Research Site
Mogadore, Ohio, 44260, United States
Research Site
Sylvania, Ohio, 43560, United States
Research Site
Zanesville, Ohio, 43701, United States
Research Site
Norman, Oklahoma, 73069, United States
Research Site
Oklahoma City, Oklahoma, 73112, United States
Research Site
Downington, Pennsylvania, 19335, United States
Research Site
Lancaster, Pennsylvania, 17604, United States
Research Site
Pittsburgh, Pennsylvania, 15212, United States
Research Site
Greer, South Carolina, 29651, United States
Research Site
Simpsonville, South Carolina, 29681, United States
Research Site
Chattanooga, Tennessee, 37403, United States
Research Site
Chattanooga, Tennessee, 37404, United States
Research Site
Germantown, Tennessee, 38138, United States
Research Site
Jackson, Tennessee, 38305, United States
Research Site
Kingsport, Tennessee, 37660, United States
Research Site
Knoxville, Tennessee, 37909, United States
Research Site
Memphis, Tennessee, 38120, United States
Research Site
Nashville, Tennessee, 37203, United States
Research Site
Austin, Texas, 78745, United States
Research Site
Corsicana, Texas, 75110, United States
Research Site
Dallas, Texas, 75231, United States
Research Site
Dallas, Texas, 75234, United States
Research Site
Fort Worth, Texas, 76104, United States
Research Site
Houston, Texas, 77090, United States
Research Site
Murray, Utah, 84107, United States
Research Site
Chesapeake, Virginia, 23320, United States
Research Site
Richmond, Virginia, 23294, United States
Research Site
Suffolk, Virginia, 23434, United States
Research Site
Virginia Beach, Virginia, 23454, United States
Research Site
Bellevue, Washington, 98004, United States
Research Site
Spokane, Washington, 99204, United States
Research Site
Spokane, Washington, 99207, United States
Research Site
Milwaukee, Wisconsin, 53215, United States
MeSH Terms
Interventions
Study Officials
- PRINCIPAL INVESTIGATOR
Anthony Lembo, MD
Beth Israel Deaconess Medical Center, Boston
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
January 23, 2008
First Posted
February 6, 2008
Study Start
April 1, 2006
Primary Completion
June 1, 2008
Study Completion
June 1, 2008
Last Updated
July 8, 2008
Record last verified: 2008-07